FDA granted Priority Review for Syndax's sNDA on June 25, 2025.
2 reports, 0 independent
Updated Jun 25
Gone quiet
- Reports
- 2
- Developments
- 2
- Repetition
- 0%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
FDA granted Priority Review for Syndax's sNDA on June 25, 2025.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- FDA granted Priority Review for Syndax's sNDA.
- FDA granted priority review for Syndax's Revuforj application on June 25, 2025.
Keep exploring
The entities involved
- FDA
-
Syndax Pharmaceuticals
business
Nothing else this week.
Related events
- The FDA is currently reviewing the supplemental New Drug Application (sNDA) for Arikayce's full product approval.
- The FDA is reviewing a drug approval application for a condition involving the company GAD.
- FDA granted Priority Review for the BLA submission of the SkinTE product.
- Amylyx Pharmaceuticals is seeking FDA approval for a new drug treatment.
- The FDA is reviewing drug data and company resubmissions, while also overseeing the functions of the U.S. Department of Health and Human Services.
Coverage
Newest first; wire copies grouped- Unknown outlet
- Unknown outlet